3
Clinical Trials associated with HR-20014A Trial Comparing the Pharmacodynamics and Pharmacokinetics of HR20014, INS068 and INS062 in Healthy Subjects
This is a single-center, randomized, open, six-sequence, three-period crossover phase I clinical trial in healthy subjects to compare the PK/PD and safety profiles of single dose of HR20014, INS068, and INS062. In this study, 12 subjects were randomly assigned to 6 administration sequences in a ratio of 1:1:1:1:1:1, and HR20014, INS068 or INS062 injection were given subcutaneously three times before and after each sequence.
/ Not yet recruitingPhase 1IIT To compare Pharmacokinetics and pharmacokinetics profiles of HR20014, INS068, and INS062 in healthy subjects after a single subcutaneous injection -- a single-center, randomized, open-labelled, six-sequence, three-cycle crossover design
Bioequivalence Studyof INS062 Injection and NovoRapid ®in Healthy Subjects and Pharmacokinetics and Pharmacodynamics Study of Single Subcutaneous Injection of HR20014 in Healthy Subjects
This study was divided into two parts. The aim of this study is to investigate the bioequivalence of INS062 injection andNovoRapid ® in healthy subjects(Part I), and to investigate the pharmacokinetics and pharmacodynamics of single dose of HR20014 injection and BIAsp 30 in healthy subjects(Part II).
100 Clinical Results associated with HR-20014
100 Translational Medicine associated with HR-20014
100 Patents (Medical) associated with HR-20014
100 Deals associated with HR-20014